Azienda Sociosanitaria 3
- Address
- lock Available on a paid plan
Neoplasms Research at Azienda Sociosanitaria 3
Clinical trial activity at this hospital in Genoa is strongly centered on cancer research, especially non-small cell lung cancer, small cell lung cancer, and bladder cancer. The studies are focused on testing new treatment options, comparing them with standard care, and improving outcomes for people with advanced or high-risk disease.
- Adjuvant treatment approaches for completely resected non-small cell lung cancer
- New therapies for advanced and metastatic lung cancer, including KRAS G12C-mutated disease
- Treatment strategies for relapsed small cell lung cancer
- Therapy evaluation in high-risk non-muscle-invasive bladder cancer with FGFR alterations
Overall, the research here aims to refine oncology care by assessing whether emerging medicines can better control disease, delay progression, and improve survival.
Respiratory Tract Diseases Trials
A major part of the research portfolio addresses respiratory tract diseases, with an emphasis on different forms of lung cancer. These studies are designed to evaluate how well new combinations and maintenance approaches work in patients whose disease has returned, spread, or required earlier treatment.
- Studies in advanced non-small cell lung cancer and metastatic non-small cell lung cancer
- Research in advanced/metastatic non-squamous NSCLC
- Comparisons of new immunotherapy-based and chemotherapy-based treatment options
- Investigations aimed at improving overall survival and progression-free survival
The work at this site reflects a strong effort to improve treatment effectiveness in thoracic oncology while helping identify better options for patients with difficult-to-treat respiratory cancers.
Health Care and Public Health Research
Alongside cancer studies, the site also contributes to health care and public health research through a smaller trial focused on symptom relief in non-streptococcal pharyngotonsillitis. This study looks at how well a commonly used lozenge can reduce pain in children, supporting better everyday treatment of an acute throat condition.
- Evaluation of pain relief in pediatric pharyngotonsillitis
- Assessment of a marketed treatment for symptom improvement
- Research focused on practical public health care in a common infection-related condition
This adds a patient-centered dimension to the research portfolio at SSD Oncologia PO Villa Scassi, complementing its broader focus on complex oncology trials.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 therapeutic areas and 15 of 21 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Azienda Sociosanitaria 3
lock Showing 1 of 10 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Investigator’s Choice of Intravesical Chemotherapy in Participants with High-risk Non-muscle-invasive Bladder Cancer with Susceptible FGFR Alterations Who Had Received Intravesical Bacillus Calmette-Guérin (BCG) | Janssen Cilag International | Phase III | Recruiting | Dec 2025 | — |
IMP list
lock Showing 1 of 21 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Lurbinectedin | 2 | Unknown | 2022-02-14 | 2022-07-19 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.